Liquidia Corp (LQDA) Stock Price & Analysis
Liquidia Corp (LQDA) fell 3.16% to USD 86.22 as of July 25, 2026 at 10:40 UTC, according to Nexqual real-time market data.
LQDA last closed at USD 89.03; the session ranged USD 85.7–91.1 on volume of 1,367,902 shares. Market capitalization is $7.67B, with a 52-week range of USD 16.82–91.1 (NCM). Source: Nexqual, July 25, 2026 at 10:40 UTC.
Key Statistics (as of July 25, 2026 at 10:40 UTC)
| Price | USD 86.22 |
|---|---|
| Change | ▼ 3.16% (down) |
| Previous Close | USD 89.03 |
| Open | USD 90.4 |
| Day Range | USD 85.7 – 91.1 |
| 52-Week Range | USD 16.82 – 91.1 |
| Volume | 1,367,902 shares |
| Market Cap | $7.67B |
| Exchange | NCM |
Technical Analysis (LQDA)
Nexqual's technical model rates LQDA "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 10:40 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 63.27 (neutral) |
| vs SMA50 | Above (USD 70.49) |
| MACD | 4.21 (positive) |
Analyst Ratings (LQDA)
Wall Street analysts rate LQDA "Strong Buy" based on 8 analysts, with a mean price target of USD 84.88 (range USD 60–130), per Nexqual as of July 25, 2026 at 10:40 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 84.88 |
| High Target | USD 130 |
| Low Target | USD 60 |
| Buy / Hold / Sell | 7 / 1 / 0 |
Earnings (LQDA)
| Next Earnings Date | 2026-08-12 |
|---|---|
| EPS Estimate | USD 0.84 |
| Revenue Estimate | $168.48M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.52 vs est 0.41 ▲ beat |
| 2025-12-31 | USD 0.15 vs est 0.33 ▼ miss |
| 2025-09-30 | USD -0.04 vs est -0.35 ▲ beat |
| 2025-06-30 | USD -0.49 vs est -0.39 ▼ miss |
Source: Nexqual, July 25, 2026 at 10:40 UTC.
Financials & Fundamentals (LQDA)
| Total Revenue | $288.06M |
|---|---|
| Revenue Growth (YoY) | +4158.50% |
| Gross Margin | +91.81% |
| Operating Margin | +46.29% |
| Profit Margin | +7.74% |
| ROE | +28.18% |
| Debt / Equity | 170.22 |
| Current Ratio | 2.22 |
| Total Cash | $222.79M |
| Total Debt | $184.82M |
| Free Cash Flow | $9.58M |
Source: Nexqual, July 25, 2026 at 10:40 UTC.
Financial Health Score (LQDA)
Nexqual rates Liquidia Corp's overall financial health "Solid" across five dimensions, as of July 25, 2026 at 10:40 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Strong — Gross margin 92%, operating 46% |
| Balance Sheet | Weak — $223M cash vs $185M debt, net cash position |
| Cash Flow | Solid — FCF $10M, 6% margin |
| Efficiency | Strong — ROE 28%, ROA 9.1% |
Ownership (LQDA)
| Insider Ownership | +12.66% |
|---|---|
| Institutional Ownership | +71.10% |
| Shares Outstanding | 88.93M |
| Float | 62.34M |
| Short % of Float | +17.23% |
Source: Nexqual, July 25, 2026 at 10:40 UTC.
Leadership (LQDA)
Liquidia Corp is led by Roger A. Jeffs (age 63), CEO & Director, per Nexqual as of July 25, 2026 at 10:40 UTC.
| CEO & Director | Roger A. Jeffs (age 63) |
|---|---|
| COO & CFO | Michael Kaseta (age 49) |
| Senior Vice President of Marketing | Michael Post |
| Senior Vice President of Sales | Matt Snow |
Major Backers & Investors (LQDA)
Notable institutional backers of Liquidia Corp include Farallon Capital Management LLC, Caligan Partners, LP, Findell Capital Management LLC, according to Nexqual as of July 25, 2026 at 10:40 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Farallon Capital Management LLC | 9.73% |
| Caligan Partners, LP | 9.13% |
| Findell Capital Management LLC | 3.94% |
| Opaleye Management Inc. | 2.86% |
| Bank of America Corporation | 2.57% |
| MPM Bioimpact LLC | 1.58% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.53% |
| Vanguard Group | 6.5% |
| State Street | 3.29% |
| Geode Capital | 2.17% |
Source: Nexqual, July 25, 2026 at 10:40 UTC.
From Liquidia Corp's Latest SEC 10-K Filing (filed 2026-03-05)
Key Strengths & Strategy (as disclosed to the SEC)
- Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States.
- The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
- It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
- In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CRNX | Crinetics Pharmaceuticals, Inc. | USD 83.73 | ▲ 0.01% |
| KNSA | Kiniksa Pharmaceuticals Interna | USD 62.84 | ▲ 0.64% |
| MIRM | Mirum Pharmaceuticals, Inc. | USD 113.03 | ▼ 1.27% |
| SRRK | Scholar Rock Holding Corporatio | USD 47.67 | ▼ 1.3% |
| PTGX | Protagonist Therapeutics, Inc. | USD 136.11 | ▲ 0.49% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 10:40 UTC. This page is informational and not investment advice.